(ADDV-B) ADDvise - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0007464862
ADDV-B: Laboratory Equipment, Medical Devices, Pharmaceuticals, Infrastructure
ADDvise Group AB (publ) is a leading supplier of equipment and solutions to healthcare and research facilities across the globe, including Europe, North America, South America, Asia, and other international markets. The company operates through two primary business units: Lab and Healthcare. The Lab business unit specializes in providing advanced laboratory furnishings, ventilation systems, climate-controlled environments, and specialized equipment tailored for the pharmaceutical and life sciences industries. This unit serves clients in sectors such as biotechnology, medical research, and pharmaceutical manufacturing, offering customized solutions to meet specific laboratory needs.
The Healthcare business unit focuses on developing and distributing medical equipment, pharmaceuticals, and consumables across various clinical specialties, including urology, gynecology, emergency care, and surgical applications. This unit also manufactures and markets surgical tables, as well as a range of cables, connectors, and wires used in medical settings. Additionally, the company provides rental and sales solutions for medical and laboratory equipment, particularly for clinical studies, and designs and installs customized cleanrooms, climate-controlled environments, and advanced air conditioning systems.
ADDvise Group AB (publ) further expands its portfolio by distributing medical devices such as continuous glucose monitors, insulin pumps, and orthopedic solutions, including implants and surgical instruments. The company also develops software and instruments for assessing patient mobility, pain levels, and muscle strength. In the realm of diagnostics, it offers healthcare and industrial ultrasound devices for both medical applications and non-destructive testing (NDT) inspections. Other key offerings include a mail-order pharmacy service, over-the-counter generic medications for pain management and respiratory conditions, and colorimetric CO2 indicators used to monitor breathing in critical care settings.
Originally established in 1989 as ADDvise Lab Solutions AB (publ), the company rebranded to ADDvise Group AB (publ) to reflect its expanded scope and diversified product lines. Headquartered in Stockholm, Sweden, ADDvise Group AB (publ) has grown into a significant player in the global healthcare and life sciences equipment market, with a strong commitment to innovation and customer-centric solutions.
Additional Sources for ADDV-B Stock
ADDV-B Stock Overview
Market Cap in USD | 44m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception |
ADDV-B Stock Ratings
Growth 5y | 34.5% |
Fundamental | 46.8% |
Dividend | 1.0% |
Rel. Strength Industry | -78.3 |
Analysts | - |
Fair Price Momentum | 1.38 SEK |
Fair Price DCF | 0.64 SEK |
ADDV-B Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | -100.00% |
Payout Consistency | 1.0% |
ADDV-B Growth Ratios
Growth Correlation 3m | -83.1% |
Growth Correlation 12m | -96.2% |
Growth Correlation 5y | 57.3% |
CAGR 5y | 26.92% |
CAGR/Max DD 5y | 0.29 |
Sharpe Ratio 12m | -2.09 |
Alpha | -83.18 |
Beta | -0.06 |
Volatility | 137.68% |
Current Volume | 625.9k |
Average Volume 20d | 712k |
As of March 14, 2025, the stock is trading at SEK 2.03 with a total of 625,948 shares traded.
Over the past week, the price has changed by -12.88%, over one month by +45.00%, over three months by -37.15% and over the past year by -78.38%.
Partly, yes. Based on ValueRay Fundamental Analyses, ADDvise (ST:ADDV-B) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 46.83 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ADDV-B as of March 2025 is 1.38. This means that ADDV-B is currently overvalued and has a potential downside of -32.02%.
ADDvise has no consensus analysts rating.
According to ValueRays Forecast Model, ADDV-B ADDvise will be worth about 1.6 in March 2026. The stock is currently trading at 2.03. This means that the stock has a potential downside of -19.7%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 8.7 | 328.6% |
Analysts Target Price | - | - |
ValueRay Target Price | 1.6 | -19.7% |